<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078738</url>
  </required_header>
  <id_info>
    <org_study_id>OMT28-C0101</org_study_id>
    <nct_id>NCT03078738</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects</brief_title>
  <official_title>A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeicos Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeicos Therapeutics GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this first-in-human study is to assess the safety, tolerability, PK and
      exploratory pharmacodynamics (PD) of single and multiple oral ascending doses of OMT-28 in
      healthy male subjects to support further clinical development of OMT-28 in the indication of
      atrial fibrillation (AF) and to obtain data on food and gender effects of OMT-28 to guide
      dosing for Phase II trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first-in-human study will be carried out in one study center involving multiple steps.
      Up to 100 healthy male and female subjects will be enrolled. The study consists of 4 parts:

        1. a single ascending dose (SAD) part

        2. a multiple ascending dose (MAD) part

        3. a single dose, double cross-over food effect (FE) part.

        4. a single dose gender effect part (female subjects group) The safety and PK data will be
           evaluated by the DSMC after each cohort to decide on further dose escalation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">February 12, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>SAD, MAD and Gender parts: double blind randomized. Food Effect part: open label, crossover design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by frequency and nature of treatment-emergent adverse events</measure>
    <time_frame>From Day 1 to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) measured by AUC0-t of OMT-28 in plasma in the SAD</measure>
    <time_frame>From Day 1 to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) measured by AUC0-∞ of OMT-28 in plasma in the SAD</measure>
    <time_frame>From Day 1 to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) measured by Cmax of OMT-28 in plasma in the SAD</measure>
    <time_frame>From Day 1 to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) measured by AUC0-24h of OMT-28 in plasma after single dosing in the SAD</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) measured by AUC0-τ after multiple dosing on Day 7 and 14 in the MAD</measure>
    <time_frame>From Day 7 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of OMT28 measured Cmax after multiple dosing on Day 7 and 14 in the MAD</measure>
    <time_frame>From Day 7 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-t of OMT-28 in plasma</measure>
    <time_frame>From Day 1 to Day 21 (Gender) and Day 28 (F&amp;E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) in Food Effect and Gender Part measured by AUC0-∞ of OMT-28 in plasma</measure>
    <time_frame>From Day 1 to Day 21 (Gender) and Day 28 (F&amp;E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of OMT28 in Food Effect and Gender Part measured by Cmax of OMT-28 in plasma</measure>
    <time_frame>From Day 1 to Day 21 (Gender) and Day 28 (F&amp;E)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline of QTcF (∆QTcF)</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from-baseline of heart rate</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from-baseline of PR interval in ECG</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from-baseline of QRS interval (∆HR, ∆PR and ∆QRS)</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>OMT-28-SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OMT-28-SAD, Single ascending dose levels 1 - 5 of OMT-28 (15, 45, 120, 240, 360 mg) Oral, healthy young male</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT-28-MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose of dose levels 1 - 4 of OMT-28 over 14 days Oral, healthy young male</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT-28- Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of OMT-28 Oral, healthy young male</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT-28-Gender</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of OMT-28 Oral, healthy non-child bearing potential female</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose levels 1 - 5 of matching placebo, Oral, healthy young male</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose levels 1 - 4 of matching placebo over 14 days Oral, healthy young male</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Gender</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of matching Placebo Oral, healthy non-child bearing potential female</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMT-28</intervention_name>
    <description>OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).</description>
    <arm_group_label>OMT-28-SAD</arm_group_label>
    <arm_group_label>OMT-28-MAD</arm_group_label>
    <arm_group_label>OMT-28- Food Effect</arm_group_label>
    <arm_group_label>OMT-28-Gender</arm_group_label>
    <other_name>17,18-epoxyeicosatetraenoic acid analog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Microcrystalline cellulose</description>
    <arm_group_label>Placebo-SAD</arm_group_label>
    <arm_group_label>Placebo MAD</arm_group_label>
    <arm_group_label>Placebo-Gender</arm_group_label>
    <other_name>Microcrystalline cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In general good physical health as determined by medical and surgical history,
             physical examination, 12 lead ECG, vital signs, and clinical laboratory tests

          2. Normal blood pressure (Systolic Blood Pressure (SBP) between 100 to 140 mmHg (both
             inclusive); Diastolic Blood Pressure (DBP) ≥55, ≤89 mmHg) measured after 5 min rest in
             supine position.

          3. SAD, MAD, and FE part: male of 18 to 45 years (inclusive) of age.

          4. Gender effect part: female of 18 to 45 years (inclusive) of age.

        Exclusion Criteria:

          1. More than moderate smoker (&gt; 10 cigarettes/day).

          2. More than moderate alcohol consumption (&gt; 35 g of ethanol regularly per day or &gt; 245 g
             regularly per week).

          3. Use of any medication

          4. One or more key safety laboratory parameters out of normal range Gender effect part
             Pregnant or breastfeeding women and of childbearing potential Previous assignment to
             treatment during this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Schaumann, Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRS-Mönchengladbach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Summo, PhD</last_name>
    <phone>3094894818</phone>
    <email>l.summo@omeicos.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS-Mönchengladbach</name>
      <address>
        <city>Monchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Schaumann, Dr med</last_name>
    </contact>
    <contact_backup>
      <phone>0800 0216100</phone>
      <email>probandeninfo.mg@crs-group.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OMT-28</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>SAD</keyword>
  <keyword>MAD</keyword>
  <keyword>First-in-Man</keyword>
  <keyword>Cardiovascular</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

